COMMUNIQUÉS West-GlobeNewswire

Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association
06/10/2018
- 16/17 (94%) Responding RET-Mutant Medullary Thyroid Cancer Patients Remain on Therapy, With Median Follow-Up of 8.4 Months - - 7/7 (100%) Responding RET Fusion-Positive Thyroid Cancer Patients Remain on Therapy, With [...]
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
06/10/2018
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA) Study participants achieved motor milestones with 100 percent sitting [...]
Akcea et Ionis annoncent l’homologation de TEGSEDIMC (inotersen pour injection) au Canada
06/10/2018
Le premier et le seul traitement de ce type pour les Canadiens atteints d’amylose héréditaire liée à la transthyrétine (hATTR) avec polyneuropathie, une maladie héréditaire rare OTTAWA et BOSTON et CARLSBAD, Californie [...]
Adamas Announces New Employment Inducement Grant
05/10/2018
EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option [...]
Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)
05/10/2018
Express Scripts’ Accredo® selected as specialty pharmacy for its expertise in providing timely access and support services for patients living with rare diseases BOSTON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea [...]
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
05/10/2018
TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life TEGSEDI is an effective treatment choice that allows self-administration at a time and [...]
Cogentix Medical, Inc. / Laborie Medical Technologies Canada ULC Merger Litigation
05/10/2018
TORONTO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- On March 11, 2018, Cogentix Medical, Inc. (“Cogentix”) and certain affiliates of Laborie Medical Technologies Canada ULC (“Laborie”), LM US Parent, Inc. (“Parent”) and Camden [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2018
BURLINGTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,600 shares of common stock [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/10/2018
BOTHELL, Wash., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Solid Biosciences to Present at the Chardan Genetic Medicines Conference
05/10/2018
CAMBRIDGE, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the Chardan Capital Markets 2 nd [...]
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
05/10/2018
SAN DIEGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at [...]
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/10/2018
RADNOR, Pa., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat [...]
Genetic Testing: Thinking About An At-Home Test for Alzheimer’s Risk Gene?
05/10/2018
What You Need to Know—First NEW YORK, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Persons wishing to learn their genetic risk for Alzheimer’s disease —by way of an at-home genetic test—should first consider consulting with their [...]
Sienna Announces Third Quarter 2018 Results Release Date and Conference Call
05/10/2018
MARKHAM, Ontario, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced that it will report its 2018 third quarter results after market close on Wednesday, [...]
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
05/10/2018
LONDON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel [...]
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
05/10/2018
Represents a potentially powerful strategy to modulate vector immunogenicity and may open new therapeutic avenues for AAV vector-mediated gene transfer EVRY, France and WATERTOWN, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE [...]
About acquisition of significant shareholding
05/10/2018
On October 5, 2018, JSC Olainfarm has received a notification from shareholder Irina Maligina on increased material shareholding up till 7.79% from share capital with voting rights, since the 25 th of September, 2018. [...]
XBiotech annonce la conclusion du recrutement pour l'étude multicentrique de phase 2 d'évaluation de Bermekimab chez les patients atteints d'une dermatite atopique
05/10/2018
AUSTIN, Texas, 05 oct. 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui avoir terminé le recrutement pour son étude clinique ouverte de phase 2 consacrée à l'évaluation de l'administration [...]
KemPharm Announces Pricing of Public Offering of Common Stock
05/10/2018
CORALVILLE, Iowa, Oct. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the pricing of its [...]

Pages